Prilosec/Nexium Alert Is Debut Of FDA’s Early Communication Of Safety Issues

FDA's announcement of an ongoing safety investiation regarding a possible increased risk of cardiac events with AstraZeneca's Prilosec (omeprazole) and Nexium (esomeprazole) is the first test case of the agency's new policy of releasing emerging drug safety information